Nano-X Imaging Ltd.

NNOX

Equity

ISIN IL0011681371 / Valor 56410599

NASDAQ (2024-11-18)

USD 5.68-2.91%

Nano-X Imaging Ltd.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Nano-X Imaging Ltd. is a company focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable globally. The company's ecosystem includes the Nanox.ARC, a multi-source Digital Tomosynthesis system, an AI-based suite of algorithms (Nanox.AI), a cloud-based infrastructure (Nanox.CLOUD), and a decentralized marketplace through its subsidiary, USARAD Holdings Inc., providing remote access to radiology and cardiology experts. The company's vision is to increase access, reduce costs, and enhance the efficiency of routine medical imaging technology and processes to improve early detection and treatment, ultimately aiming to help people achieve better health outcomes and save lives.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the second quarter of 2023, Nano-X Imaging Ltd. reported total revenues of $2,582 thousand, showing an increase from the $2,200 thousand reported in the same quarter of 2022. This growth was primarily driven by the performance of the radiology services division.

Operating Loss

For Q2 2023, Nano-X Imaging Ltd. recorded a segment operating loss of $17,831 thousand, which is an improvement compared to the $22,183 thousand loss in Q2 2022. The reduction in operating loss is attributed to better cost management and increased revenues.

Net Loss

Nano-X Imaging Ltd. reported a net loss before taxes of $17,451 thousand for the second quarter of 2023, compared to a net loss of $21,712 thousand in the same period of 2022. This reduction in net loss is a positive indicator of the company's efforts to streamline operations.

Depreciation and Amortization

Depreciation and amortization expenses for Nano-X Imaging Ltd. in Q2 2023 were $2,907 thousand, slightly lower than the $2,970 thousand reported in Q2 2022. This slight decrease reflects the company's ongoing management of its asset base.

Stock-Based Compensation

In the second quarter of 2023, Nano-X Imaging Ltd. incurred stock-based compensation expenses of $1,820 thousand, down from $4,991 thousand in Q2 2022. This significant decrease is part of the company's strategy to control operational costs and improve financial performance.

Summarized from source with an LLMView Source

Key figures

-13.1%1Y

-70.1%3Y

%5Y

Performance

92.0%1Y

90.7%3Y

102%5Y

Volatility